Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT00493116
- Locations
- 🇳🇿
Research Site, Hamilton, New Zealand
🇦🇺Coordinating Research Site, NSW, Australia
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2008-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 14
- Registration Number
- NCT00492466
- Locations
- 🇫🇮
Coordinating Research Site, Turku, Finland
Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2008-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 3
- Registration Number
- NCT00493077
- Locations
- 🇸🇪
Coordinating Research Site, Huddinge, Sweden
🇸🇪Research Site, Stockholm, Sweden
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 380
- Registration Number
- NCT00492765
- Locations
- 🇩🇰
Coordinating Research Site, Copenhagen, Denmark
GER-009-06-AVX Early Therapy in Multiple Sclerosis
- Conditions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2009-06-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 230
- Registration Number
- NCT00492570
GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 50
- Registration Number
- NCT00488566
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
TYGRIS - ROW: TYSABRI Global Observational Program in Safety - Rest of World
- Conditions
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 4296
- Registration Number
- NCT00483847
- Locations
- 🇩🇪
There are multiple sites throughout Europe in this clinical trial. Contact Advanced Medical Services (AMS)., Mannheim, Germany
TYSABRI Global Observational Program in Safety
- Conditions
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 2207
- Registration Number
- NCT00477113
- Locations
- 🇺🇸
There may be mulitple sites in this clinical trial. Contact United BioSource Corporation, Kansas City, Missouri, United States
Pregnancy Exposure Registry for Tysabri®
- Conditions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 376
- Registration Number
- NCT00472992
- Locations
- 🇺🇸
United BioSource Corporation, Morgantown, West Virginia, United States
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
- Conditions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 89
- Registration Number
- NCT00464074
- Locations
- 🇵🇷
Research Site, Guaynabo, Puerto Rico